Quantcast
Home > Quotes > PDLI
PDLI

PDL BioPharma, Inc. Common Stock (PDLI) Quote & Summary Data

$2.87
*  
0.14
4.65%
Get PDLI Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading PDLI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PDLI Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3
Today's High / Low
$ 3.03 / $ 2.87
Share Volume
2,704,132
50 Day Avg. Daily Volume
1,438,528
Previous Close
$ 3.01
52 Week High / Low
$ 3.16 / $ 2.25
Market Cap
418,951,728
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.42
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.83

Intraday Chart

Shares Traded

Share Volume:
2,704,132
50 Day Avg. Daily Volume:
1,438,528

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.42

Trading Range

The current last sale of $2.87 is 27.56% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.03 $ 3.16
 Low: $ 2.87 $ 2.25

ETFs with PDLI as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.86% Invesco Russell 2000 Pure Value ETF (PXSV) -1.79 (-5.56%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

In this report all references to "PDL," "we," "us," "our" or the "Company" mean collectively PDL BioPharma, Inc. and its subsidiaries, except where it is made clear that the term means only PDL BioPharma, Inc. We seek to provide a significant return for our stockholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. In 2012, we began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, we have consummated seventeen of such transactions, of which nine are active and outstanding. We have one debt transaction outstanding, representing deployed capital of $20.0 million: CareView Communications, Inc.  ... More ...  


Risk Grade

Where does PDLI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.99
Open Date:
Nov. 19, 2018
Close Price:
$ 2.87
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x